You don’t always feel it happening. A bit of fatigue, maybe some weight gain, and life goes on.
But beneath the surface, your liver could be storing more fat than it should, quietly increasing long-term health risks.
According to the University of Barcelona, researchers are now exploring a new way to tackle this widespread issue using medications that are already on the market, according to Science Daily.
A growing threat
Fatty liver disease, now affecting around one in three adults, develops when excess fat accumulates in liver cells.
Over time, this can lead to serious complications, including a higher risk of heart disease.
With limited treatment options available, scientists have been searching for alternatives that are both effective and safe, especially in the early stages when symptoms are often absent.
An unexpected pairing
Led by Professor Marta Alegret, the research team examined two existing drugs: pemafibrate, used for lipid control, and telmisartan, commonly prescribed for high blood pressure.
Tests on animal models showed that combining the two significantly reduced liver fat caused by unhealthy diets.
Interestingly, using smaller doses together achieved results similar to higher doses of each drug individually.
The combined approach was linked to:
- Lower liver fat levels
- Improved cholesterol and blood pressure markers
- Reduced overall cardiovascular risk
Still early days
The study also suggests the drugs influence different metabolic pathways, which may explain their combined effect. However, the findings are still limited to animal research.
Human trials will be necessary before this approach can be considered for widespread treatment.
Researchers are continuing to investigate whether the same method could help more advanced cases.
